17 February, 2017 | BEIJING - On February 16, 2017 WHO issued its first-ever global guidance on testing for chronic viral hepatitis B and C. Viral hepatitis causes an estimated 1.4 million deaths worldwide. The guidelines were released in a special session at the 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL), held in Shanghai, China.
State Council’s Guidance Strengthens China’s Immunization Program, Provides a Model for Use of Independent Scientific Evidence for Immunizations
17 February, 2017 | BEIJING - On February 7, 2017, China’s State Council released a visionary yet practical guideline for the development, management, and recommendation of vaccines for use in China – guidance that will help policy-makers bring the benefits of new, safe and effective vaccines to all children.
13 February, 2017 | BEIJING - On February 9th, 2017, the Health and Family Planning Commission of Zhejiang Province issued a statement regarding a breach in patient safety protocols that led to HIV infections in patients at the Zhejiang Provincial Hospital of Traditional Chinese Medicine.
China and WHO Adopt Transformative Approach: Linking Health and Economic Development with New Agreement on One Belt One Road Initiative
19 January 2017 | BEIJING - China’s President Xi Jinping and WHO’s Director General Margaret Chan today agreed to bring a global health focus to economic development, starting with the One Belt One Road (OBOR) initiative supported by China.
- WHO issues viral hepatitis testing guidelines, with significant implications for China
- State Council’s Guidance Strengthens China’s Immunization Program, Provides a Model for Use of Independent Scientific Evidence for Immunizations
- Creating a Culture of Patient Safety in China
- China and WHO Adopt Transformative Approach: Linking Health and Economic Development with New Agreement on One Belt One Road Initiative
Highlights from the country
22 March 2016
On 22 March 2016, WHO Regional Director for the Western Pacific Dr Shin Young-soo and National Health and Family Planning Commission (NHFPC) Minister Li launched the new WHO-China Country Cooperation Strategy (CCS). The CCS outlines the priorities for WHO’s work in China over the next 5 years.
14 March 2016
In 2014 WHO recommended offering pre-exposure prophylaxis (PrEP) to men who have sex with men (MSM). On the basis of further evidence of the effectiveness and acceptability of PrEP, WHO has now broadened the recommendation to include all population groups at substantial risk of HIV infection.
Offering PrEP should be a priority for populations with an HIV incidence of about 3 per 100 person-years or higher. PrEP should be an additional prevention choice in a comprehensive package of services that also includes HIV testing, counselling, male and female condoms, lubricants, ARV treatment for partners with HIV infection, voluntary medical male circumcision and harm reduction interventions for people who use drugs.
14 March 2016
WHO Technical Consultation on a comprehensive National Hepatitis Programme in China with a focus on viral hepatitis B and C treatment, Beijing, China, 21 February 2014 : meeting report
China has a heavy burden of viral hepatitis. About 90 million people are chronically infected with the hepatitis B virus and about 7 to 10 million people are estimated to be infected with the hepatitis C virus. The consequence of chronic hepatitis is substantial - liver cancer is the second leading cause of death in China in the agegroup of 35-54 years of age. Effective treatment for hepatitis B and C is available. Studies show that treatment for hepatitis B and C is cost effective, and may reduce death due to chronic hepatitis-related liver disease including liver cancer.
In view of importance of chronic hepatitis in China, a technical consultation was held on 21 February 2014 in Beijing with national stakeholders to discuss the scientific evidence, current challenges and new opportunities for scaling up hepatitis treatment in China using the public health approach.